Skip to main content
Coverage for your commercially insured patients

why Nurtec® ODT (rimegepant)

Camille W
Actual Nurtec ODT Patient

*Per IQVIA as oral brand in class (oral CGRP receptor antagonists): number one prescribed,
number one in new prescriptions, and more neurologists selected as brand of choice

Patients are often forced to sit on the sidelines, unable to participate in the things they love1

Of the 11,266 people
with migraine...2

59% say that migraine has stopped them from participating in previous hobbies2

57% say that migraine has stopped them from attending social events2

34% say that migraine has stopped them from engaging in sports or exercising2

Traditional oral treatments are often associated with poor tolerability and high discontinuation rates that limit use for patients with migraine.3

Nurtec ODT can also prevent migraines, so I feel way more confident about getting on the road!

Evan B

Actual Nurtec ODT patient
Individual results may vary

I have gone from fearful to empowered and secure because Nurtec ODT helps me treat or prevent migraines.

Mary H

Actual Nurtec ODT patient
Individual results may vary

Although most patients have identified triggers that cause their migraine, some cannot be avoided1,4,5,*

Common Triggers

Irregular sleep schedule, hormonal change. seasonal change. stress, light


97% of people with migraine are aware of their triggers4,†

For your patients who can't avoid seasonal, stress, and menstrual-related migraine triggers, consider a flexible approach that allows you to treat migraine based on their needs.1,4,5

*Based on the annual "Migraine in America" survey, a June 22, 2020-September 14, 2020 U.S. online survey completed by 4693 adults with migraine by

Based on the annual "Migraine in America" survey, a 2016 U.S. online survey completed by 3923 adults with migraine by

Blocking the CGRP receptor has been shown to reduce pain and symptoms during a migraine attack and reduce migraine frequency6,7

One dose can inhibit three CGRP-induced effects by selectively binding to CGRP receptors8-11

Inhibits pain signaling8,12

Inhibits vasodilation without active vasoconstriction6,8,12

Inhibits neurogenic inflammation8,12

The selective binding of CGRP receptor antagonists treats migraine without the vasoconstrictive effects of triptans.6,7

The CGRP mechanism of action is not associated with MOH.13

MOA=mechanism of action; CGRP=calcitonin gene-related peptide; MOH=medication overuse headache

I can go about my life now without fearing that a migraine is around the corner.

Mary H

Actual Nurtec ODT patient
Individual results may vary

The medication I trust to stop migraine attacks is proven to prevent migraines, too? That's amazing!

Brittany N

Actual Nurtec ODT patient
Individual results may vary

See the Doctor Discussion Guide on to find out about topics your patients may raise with you regarding their migraine experiences and treatment goals.

References: 1. Migraine in America 2020 Findings for Media. Health Union, LLC. 2. Martelletti P, Schwedt TJ, Lanteri-Minet M et al. My Migraine Voice survey: a global study of disease burden among individuals with migraine for whom preventive treatments have failed. J Headache Pain. 2018 Nov 27;19(1):115. doi:10.1186/s10194-018-0946-z. 3. Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E; Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012 Apr 24;78(17):1337-45. doi:10.1212/WNL.0b013e3182535d20. Erratum in: Neurology. 2013 Feb 26;80(9):871. 4. Editorial Team 2016. Migraine in America 2016. Accessed June 7, 2021. 5. Top 10 Migraine Triggers and How to Deal with Them: AMF. American Migraine Foundation. Published July 10, 2020. Accessed June 7, 2021. 6. Tepper SJ. CGRP and headache: a brief review. Neurol Sci. 2019;40(Suppl 1):99-105. doi:10.1007/s10072-019-03769-8. 7. Dubowchik GM, Conway CM, Xin AW. Blocking the CGRP Pathway for Acute and Preventive Treatment of Migraine: The Evolution of Success. J Med Chem. 2020;63(13):6600-6623. doi:10.1021/acs.jmedchem.9b01810. 8. Durham PL. CGRP-Receptor Antagonists — A Fresh Approach to Migraine Therapy? N Engl J Med. 2004;350(11):1073-1075. doi: 10.1056/NEJMp048016. 9. Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of Migraine: A Disorder of Sensory Processing. Physiol Rev. 2017;97(2):553-622. doi: 10.1152/physrev.00034.2015. 10. Iyengar S, Johnson KW, Ossipov MH, Aurora SK. CGRP and the Trigeminal System in Migraine. Headache. 2019;59(5):659-681. doi: 10.1111/head.13529. 11. Edvinsson L, Haanes KA, Warfvinge K, Krause DN. CGRP as the target of new migraine therapies — successful translation from bench to clinic. Nat Rev Neurol. 2018 Jun;14(6):338-350. doi: 10.1038/s41582-018-0003-1. 12. Nurtec ODT. Package insert. Biohaven Pharmaceuticals Inc. 13. van Hoogstraten WS, MaassenVanDenBrink A. The need for new acutely acting antimigraine drugs: moving safely outside acute medication overuse. J Headache Pain. 2019;20(1):54. doi:10.1186/s10194-019-1007-y.